【摘要】 自然杀伤细胞受体第二组成员A(natural killer cell receptor groupⅡnumber A, NKG2A)是NKG2受体家族的抑制性受体成员，主要表达在以NK细胞为代表的多种免疫细胞上，研究发现NKG2A参与多种肿瘤的发生、发展。目前针对NKG2A的靶向药物已进入一系列上皮性肿瘤的临床期试验。该文通过阐述NKG2A的生物学特性及其在CD8~+T细胞、 NK细胞等免疫细胞中的生物学作用，进而探讨NKG2A作为免疫检查点在抗肿瘤免疫中的作用机制，以期为临床抗肿瘤免疫治疗提供理论依据。更多还原

【Abstract】 Natural killer cell receptor group Ⅱ member A(NKG2A) is an inhibitory receptor of the NKG2 receptor family, which is mainly expressed on a variety of immune cells represented by NK cells. Studies have also revealed that NKG2A is involved in the development of a variety of tumors. NKG2A targeting drugs are currently in clinical phase trials for multiple epithelial tumors. The review describes the biological properties of NKG2A and its regulatory role on CD8~+ T cells, NK cells, and other immune cells. The review further explores the mechanism of NKG2A as an immune checkpoint in anti-tumor immunity, and provides a theoretical basis for clinical anti-tumor immunotherapy.更多还原